煙酸可治療成人線粒體肌病系統性NAD缺乏及改善肌肉功能
作者:
小柯機器人發布時間:2020/5/9 21:10:16
芬蘭赫爾辛基大學Anu Suomalainen和Eija Pirinen合作取得新進展。他們發現煙酸可治療成人線粒體肌病系統性NAD缺乏及改善肌肉功能。該研究於2020年5月7日發表於《細胞-代謝》。
他們報導了成年線粒體肌病患者的全身NAD +缺乏症。他們分別給患者及其匹配的對照者增加了10個月或4個月劑量的NAD +增強煙酸(一種維生素B3形式)(至750–1,000 mg /天;clinicaltrials.gov NCT03973203)。在所有受試者中,血液NAD +均增加大到8倍,並且患者的肌肉NAD +達到了對照水平。
一些患者表現出貧血趨勢,而所有受試者的肌肉力量和線粒體生物合成均增加。在患者中,肌肉代謝組向對照組轉移,肝脂肪減少甚至達到50%。他們的證據表明,血液分析可用於鑑定NAD +缺乏症,並指出煙酸是治療線粒體肌病的有效NAD +增強劑。
研究人員表示,NAD +是一種具有氧化還原活性的代謝產物,已提出將其消耗掉以促進齧齒動物的衰老和退行性疾病。然而,退行性疾病患者是否會發生NAD +耗竭以及NAD +耗竭是否能改善其症狀仍未確定。
附:英文原文
Title: Niacin Cures Systemic NAD+ Deficiency and Improves Muscle Performance in Adult-Onset Mitochondrial Myopathy
Author: Eija Pirinen, Mari Auranen, Nahid A. Khan, Virginia Brilhante, Niina Urho, Alberto Pessia, Antti Hakkarainen, Juho Kuula, Ulla Heinonen, Mark S. Schmidt, Kimmo Haimilahti, Pivi Piiril, Nina Lundbom, Marja-Riitta Taskinen, Charles Brenner, Vidya Velagapudi, Kirsi H. Pietilinen, Anu Suomalainen
Issue&Volume: 2020-05-07
Abstract: NAD+ is a redox-active metabolite, the depletion of which has been proposed to promoteaging and degenerative diseases in rodents. However, whether NAD+ depletion occurs in patients with degenerative disorders and whether NAD+ repletion improves their symptoms has remained open. Here, we report systemic NAD+ deficiency in adult-onset mitochondrial myopathy patients. We administered an increasingdose of NAD+-booster niacin, a vitamin B3 form (to 750–1,000 mg/day; clinicaltrials.gov NCT03973203) for patients and their matched controls for 10 or 4 months, respectively. BloodNAD+ increased in all subjects, up to 8-fold, and muscle NAD+ of patients reached the level of their controls. Some patients showed anemia tendency,while muscle strength and mitochondrial biogenesis increased in all subjects. In patients,muscle metabolome shifted toward controls and liver fat decreased even 50%. Our evidenceindicates that blood analysis is useful in identifying NAD+ deficiency and points niacin to be an efficient NAD+ booster for treating mitochondrial myopathy.
DOI: 10.1016/j.cmet.2020.04.008
Source: https://www.cell.com/cell-metabolism/fulltext/S1550-4131(20)30190-X